PharmaResources (Shanghai) Co. Ltd. A - Asset Resilience Ratio
PharmaResources (Shanghai) Co. Ltd. A (301230) has an Asset Resilience Ratio of 16.35% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of PharmaResources (Shanghai) Co. Ltd. A to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how PharmaResources (Shanghai) Co. Ltd. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PharmaResources (Shanghai) Co. Ltd. A assets under control.
Liquid Assets Composition Over Time
This chart breaks down PharmaResources (Shanghai) Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 301230 total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥215.15 Million | 16.35% |
| Total Liquid Assets | CN¥215.15 Million | 16.35% |
Asset Resilience Insights
- Good Liquidity Position: PharmaResources (Shanghai) Co. Ltd. A maintains a healthy 16.35% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
PharmaResources (Shanghai) Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare PharmaResources (Shanghai) Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for PharmaResources (Shanghai) Co. Ltd. A (2021–2025)
The table below shows the annual Asset Resilience Ratio data for PharmaResources (Shanghai) Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.95% | CN¥248.98 Million ≈ $36.43 Million |
CN¥1.31 Billion ≈ $192.29 Million |
-0.18pp |
| 2024-12-31 | 19.13% | CN¥251.77 Million ≈ $36.84 Million |
CN¥1.32 Billion ≈ $192.63 Million |
-3.79pp |
| 2023-12-31 | 22.92% | CN¥340.79 Million ≈ $49.87 Million |
CN¥1.49 Billion ≈ $217.62 Million |
+22.10pp |
| 2022-12-31 | 0.82% | CN¥10.65 Million ≈ $1.56 Million |
CN¥1.30 Billion ≈ $190.42 Million |
+0.75pp |
| 2021-12-31 | 0.07% | CN¥397.68K ≈ $58.19K |
CN¥557.81 Million ≈ $81.62 Million |
-- |
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturin… Read more